Aphria Inc. Announces Completion of First EU-GMP Shipment to Germany
Aphria Inc. (TSX: APHA) and (Nasdaq: APHA), is a leading global cannabis company inspiring and empowering the worldwide community to live their very best life. The company announces it has completed its first certified European Union Good Manufacturing Practices shipment of dried flower from its Aphria One EU GMP facility to its wholly-owned German subsidiary, CC Pharma GmbH, a leading distributor of pharmaceutical products to more than 13,000 pharmacies in Germany.
Aphria Inc. is a leading global cannabis company striving to inspire and empower the worldwide community to live their very best life. Headquartered in Leamington, Ontario – the greenhouse capital of Canada – Aphria Inc. has been setting the standard for the low-cost production of high-quality cannabis at scale, grown in the most natural conditions possible. Focusing on untapped opportunities and backed by the latest technologies, Aphria Inc. is committed to bringing breakthrough innovation to the global cannabis market. The Company’s portfolio of brands is grounded in expertly-researched consumer insights designed to meet the needs of every consumer segment. Rooted in our founders’ multi-generational expertise in commercial agriculture, Aphria Inc. drives sustainable long-term shareholder value through a diversified approach to innovation, strategic partnerships and global expansion.
“Our first EU GMP shipment into Germany represents another significant milestone for Aphria Inc., one that strengthens our position as a leading cannabis company in Germany and in the European Union,” said Irwin D. Simon, Chief Executive Officer, Aphria Inc. “We are leveraging our strong medical platform and multi-faceted German strategy, which combines domestic cultivation, import licenses and large distribution infrastructure, to increase access to high-quality medical cannabis for patients worldwide. We remain excited about future milestones, including the completion of our cultivation facility in Neumünster, Germany, which we expect will be completed in Q2 FY2021.”
The German market is considered to be one of the most highly sought-after developed medical cannabis markets in the world. Aphria’s German operations have been preparing for the importation of EU-GMP certified cannabis from Canada, allowing for shipments to CC Pharma in order to leverage CC Pharma’s expansive in-country distribution network.
In addition to this announcement, other previously announces strategic milestones for Aphria and its wholly-owned subsidiaries in Germany include:
- Germany launched several CBD-based wellness brands in Q1 FY2021, including:
- CannRelief brand, a line of cosmetic oils and creams as well as supplements, that seek to deliver “the best from the cannabis plant to impact the lives of our consumers for the better”.
- Evoque brand, a line of natural sustainable products that help optimize skin, which includes face creams and serums.
- CannaPet brand, a line of products that bring relaxation, relief or recovery to pets.